BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18288996)

  • 1. Medical treatment of malignancy-associated hypercalcemia.
    Lumachi F; Brunello A; Roma A; Basso U
    Curr Med Chem; 2008; 15(4):415-21. PubMed ID: 18288996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-induced hypercalcemia.
    Lumachi F; Brunello A; Roma A; Basso U
    Anticancer Res; 2009 May; 29(5):1551-5. PubMed ID: 19443365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
    Morony S; Warmington K; Adamu S; Asuncion F; Geng Z; Grisanti M; Tan HL; Capparelli C; Starnes C; Weimann B; Dunstan CR; Kostenuik PJ
    Endocrinology; 2005 Aug; 146(8):3235-43. PubMed ID: 15845617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic hypercalcemia.
    Camozzi V; Luisetto G; Basso SM; Cappelletti P; Tozzoli R; Lumachi F
    Med Chem; 2012 Jul; 8(4):556-63. PubMed ID: 22571196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of malignancy associated hypercalcemia].
    Tai N; Inoue D
    Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modern management of malignant hypercalcemia.
    Legrand SB
    Am J Hosp Palliat Care; 2011 Nov; 28(7):515-7. PubMed ID: 21724679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms and treatment of hypercalcemia of malignancy.
    Clines GA
    Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current management strategies for hypercalcemia.
    Pecherstorfer M; Brenner K; Zojer N
    Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant hypercalcemia.
    Basso U; Maruzzo M; Roma A; Camozzi V; Luisetto G; Lumachi F
    Curr Med Chem; 2011; 18(23):3462-7. PubMed ID: 21756237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
    Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
    Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
    Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology and management of severe hypercalcemia.
    Nussbaum SR
    Endocrinol Metab Clin North Am; 1993 Jun; 22(2):343-62. PubMed ID: 8325291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hypercalcemia of malignancy with bisphosphonates.
    Berenson JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progress in diagnosis and therapy: Hypercalcemia due to multiple myeloma and wide-spread neoplastic bone metastasis].
    Abe M
    Nihon Naika Gakkai Zasshi; 2007 Apr; 96(4):675-80. PubMed ID: 17506303
    [No Abstract]   [Full Text] [Related]  

  • 16. [Malignancy-associated hypercalcemia].
    Oura S
    Nihon Rinsho; 2003 Jun; 61(6):1006-9. PubMed ID: 12806951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
    Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
    J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates and primary hyperparathyroidism.
    Rodan GA
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N150-3. PubMed ID: 12412793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the medical treatment of hypercalcemia of malignancy.
    Hall TG; Schaiff RA
    Clin Pharm; 1993 Feb; 12(2):117-25. PubMed ID: 8453860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating cancer-related hypercalcemia with gallium nitrate.
    Leyland-Jones B
    J Support Oncol; 2004; 2(6):509-16. PubMed ID: 15605917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.